DFTX Stock Analysis: Definium Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 5.986m USD | 12M Return: 517.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 113M
Warnings
Tailwinds
Seasonality 9.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Definium Therapeutics, Inc. (NASDAQ: DFTX) is a clinical-stage biopharmaceutical company developing novel therapies for brain health disorders. Its lead candidate, DT120, is in Phase 3 development for generalized anxiety disorder, major depressive disorder, and related conditions, while DT402, an R-enantiomer of MDMA, is in Phase 2a trials for autism spectrum disorder. As a clinical-stage company, Definium has not yet received product approvals, and its value is tied primarily to the progression of its drug pipeline through regulatory milestones.
The company is headquartered in New York, New York, and was formerly known as Mind Medicine (MindMed) Inc. before rebranding to Definium Therapeutics, Inc. in January 2026. It operates within the pharmaceuticals sub-industry of the health care sector, where central nervous system (CNS) drug development is characterized by lengthy clinical timelines, high R&D spending, and significant regulatory risk.
- Phase 3 DT120 readout in generalized anxiety disorder
- Cash burn rises as pipeline advances toward regulatory milestones
- Competition intensifies in psychedelic and brain health therapeutics market
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.36 > 0.02 and ΔFCF/TA -2.41 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.36 > 3% & CFO -143.7m > Net Income -237.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (108.8m) vs 12m ago 24.92% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -13.29 > 6 (EBIT TTM -193.4m / Interest Expense TTM 14.6m) |
| A: 0.75 (Total Current Assets 380.6m - Total Current Liabilities 81.1m) / Total Assets 401.3m |
| B: -1.64 (Retained Earnings -659.8m / Total Assets 401.3m) |
| C: -0.57 (EBIT TTM -193.4m / Avg Total Assets 338.3m) |
| D: 2.28 (Book Value of Equity 278.8m / Total Liabilities 122.4m) |
| Altman-Z'' = -1.91 = D |
As of July 08, 2026, the stock is trading at USD 44.48 with a total of 2,586,253 shares traded. Over the past week, the price has changed by -4.45%, over one month by +93.22%, over three months by +116.13% and over the past year by +517.78%.
Current recommended Stop Loss: 40.90 (which is 8% or 1.2 ATR below the current price).
Definium Therapeutics has no consensus analysts rating.
P/B = 22.3929
Revenue TTM = 0.0 USD
EBIT TTM = -193.4m USD
EBITDA TTM = -192.7m USD
Long Term Debt = 40.8m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 72.0k USD (Leases only: 72.0k)
Net Debt = -373.4m USD (calculated: Debt 72.0k - CCE 373.4m)
Enterprise Value = 5.61b USD (5.99b + Debt 72.0k - CCE 373.4m)
Interest Coverage Ratio = -13.29 (Ebit TTM -193.4m / Interest Expense TTM 14.6m)
EV/FCF = -39.06x (Enterprise Value 5.61b / FCF TTM -143.7m)
FCF Yield = -2.56% (FCF TTM -143.7m / Enterprise Value 5.61b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 13.99 (Enterprise Value 5.61b / Total Assets 401.3m)
Interest Expense / Debt = 20.2k% (Interest Expense 14.6m / Debt 72.0k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -152.8m (EBIT -193.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.69 (Total Current Assets 380.6m / Total Current Liabilities 81.1m)
Debt / Equity = 0.00 (Debt 72.0k / totalStockholderEquity, last quarter 278.8m)
Debt / EBITDA = 1.94 (negative EBITDA) (Net Debt -373.4m / EBITDA -192.7m)
Debt / FCF = 2.60 (negative FCF - burning cash) (Net Debt -373.4m / FCF TTM -143.7m)
Total Stockholder Equity = 231.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -70.22% (Net Income -237.5m / Total Assets 401.3m)
RoE = -102.5% (Net Income TTM -237.5m / Total Stockholder Equity 231.8m)
RoCE = -70.94% (EBIT -193.4m / Capital Employed (Equity 231.8m + L.T.Debt 40.8m))
RoIC = -47.71% (negative operating profit) (NOPAT -152.8m / Invested Capital 320.2m)
WACC = 10.48% (E(5.99b)/V(5.99b) * Re(10.48%) + (debt cost/tax rate unavailable))
Discount Rate = 10.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 55.52%
[DCF] Fair Price = unknown (Cash Flow -143.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.88 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.56 | Chg30d=+0.34% | Revisions=-31% | Analysts=11
EPS next Quarter (2026-09-30): EPS=-0.55 | Chg30d=+1.47% | Revisions=-42% | Analysts=11
EPS current Year (2026-12-31): EPS=-2.28 | Chg30d=-0.15% | Revisions=-53% | GrowthEPS=-10.6% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.56 | Chg30d=+1.38% | Revisions=+0% | GrowthEPS=+31.5% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -39% (up=12, down=29)